Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. The segment focuses on the company’s most recent announcement of its topline results from the CLEAR Mind phase 2a clinical trial of LGVN’s Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. According to the segment, the Lomecel-B study met its primary safety endpoint and is supported by lack of deterioration in cognitive or atrophy signals. The encouraging results will be used as a foundation for further studies, the company noted. NNA segments are designed to bring a company additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points.
The audio news release covers Longeveron’s recent news regarding positive top-line results from its phase 2a trial of its investigational product Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. “We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” said Longeveron CEO Wa’el Hashad in the news release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B in this study population. With our phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our phase 2 program in Aging-Related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B.”
To hear the audio production, visit https://ibn.fm/AOoJ8
To view the full press release, visit https://ibn.fm/wlpvD
About Longeveron Inc.
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN